… In addition to dopaminergic neuropathology, there is … with dopamine system dysfunction
and/or dopaminergic neuronal … process affecting dopaminergic and non-dopaminergic systems (…

… to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. …
AJ Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine …

… dosing and sedation, we reduce or change the offending drug. We compromise motor control
by reducing dopaminergic drugs only among the subset of patients with intolerance to all …

… dopaminergic pathways to neuroprotection. The neuroprotective properties of dopaminergic
drugs … offer permanent relief of features related to dopamine deficiency. Also, the concept …

… How the actions of dopaminergic drugs produce side effects and how … Dopaminergic drugs,
levodopa and dopamine agonists, are highly effective in the treatment of Parkinson's disease …

… to take dopaminergic drugs becomes pathologically … leads to compulsive dopaminergic drug
use 1,2 —the dopamine … brain dopamine systems mediating reward by dopaminergic drugs …

… dopamine deficiency in several ways—direct stimulation of dopamine receptors (levodopa,
dopamine receptor agonists), altering the balance between dopamine and acetylcholine in …

To quantify several acoustic features of the voice in patients withParkinson's disease (PD),
41 patients and 28 age and sex-matched controls were studied. PD severity was assessed …

The pathological processes underlying Parkinson’s disease (PD) involve more than
dopamine cell loss within the midbrain. These non-dopaminergic neurotransmitters include …

… centrally to dopamine, replacing the neurotransmitter deficient in Parkinson disease. Outside
the blood-brain barrier, in the peripheral circulation, dopamine decarboxylase inhibitors (…